Phase II study of flavopiridol in patients with advanced colorectal cancer

Annals of Oncology

Volumn 14, Issue 8, 2003, Pages 1270-1273

  Aklilu, M ^a   Kindler, H L ^a   Donehower, R C ^b   Mani, S ^a   Vokes, E E ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Clinical trial; Colorectal cancer; Flavopiridol

Indexed keywords

ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; CYTOTOXIC AGENT; FLAVONE DERIVATIVE; FLAVOPIRIDOL; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; APOPTOSIS; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CELL CYCLE; CLINICAL ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG POTENTIATION; DRUG RESPONSE; DRUG SCREENING; FATIGUE; FEMALE; FREQUENCY ANALYSIS; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; INFECTION; LIVER DYSFUNCTION; MALE; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLAVONOIDS; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PIPERIDINES; PROBABILITY; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 0043011497     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg343     Document Type: Article

References (26)

1. Jemal A, Murray T, Samuels A et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5-26.
2. Kindler HL, Schilsky RL. Colorectal cancer. In Vokes EE, Golomb HM (eds): Oncologic Therapies, 2nd edition. Berlin: Springer-Verlag 2003; 425-438.
3. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
4. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-914.
5. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
6. cdc2 protein kinase in vertebrates. EMBO J 1991; 10: 3321-3329.
7. Lorca T, Labbe JC, Devault A et al. Dephosphorylation of cdc2 on threonine 161 is required for cdc2 kinase inactivation and normal anaphase. EMBO J 1992; 11: 2381-2390.
8. cdc2 for tyrosine phosphorylation. EMBO J 1991; 10: 1545-1554.
9. Ducommun B, Brambilla P, Felix MA et al. cdc2 phosphorylation is required for its interaction with cyclin. EMBO J 1991; 10: 3311-3319.
10. 2/M transitions of the cell cycle: identification of major phosphorylation sites. EMBO J 1991; 10: 305-316.
11. Losiewicz MD, Carlson BA, Kaur G et al. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun 1994; 201: 589-595.
12. cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity. Biochem Pharmacol J 1993; 46: 1831-1840.
13. Carlson BA, Dubay MM, Sausville EA et al. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 1996; 56: 2973-2978.
14. Arguello F, Alexander M, Sterry JA et al. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood 1998; 91: 2482-2490.
15. Bible KC, Kaufmann SH. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 1996; 56: 4856-4861.
16. Konig A, Schwartz GK, Mohammad RM et al. The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood 1997; 90: 4307-4312.
17. Parker BW, Kaur G, Nieves-Neira W et al. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol. Blood 1998; 91: 458-465.
18. Patel V, Senderowicz AM, Pinto D Jr et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest 1998; 102: 1674-1681.
19. Chien M, Astumian M, Liebowitz D et al. In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer. Cancer Chemother Pharmacol 1999; 44: 81-87.
20. Sedlacek H, Czech J, Naik R et al. Flavoriridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int J Oncol 1996; 9: 1143-1168.
21. Senderowicz AM, Headlee D, Stinson SF et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 1998; 16: 2986-2999.
22. Kaplan EL. Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
23. Bible KC, Kaufmann SH. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res 1997; 57: 3375-3380.
24. Schwartz GK, Farsi K, Maslak P et al. Potentiation of apoptosis by flavopiridol in mitomycin-C treated gastric and breast cancer cells. Clin Cancer Res 1997; 3: 1467-1472.
25. Motwani M, Jung C, Sirotnak FM et al. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin Cancer Res 2001; 7: 4209-4219.
26. Shah MA, Kortmansky J, Gotten M et al. A phase I/pharmacologic study of weekly sequential irinotecan (CPT) and flavopiridol (F). Proc Am Soc Clin Oncol 2002; 21: 373.